



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: 700 MCKINNISH AVENUE OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/421,506	10/19/1999	SALVATORE ALBANI	246/285	4242

7590 02/14/2002

WESLEY B. AMES
BROBECK PHLEGER & HARRISON LLP
12390 EL CAMINO REAL
SAN DIEGO, CA 92130

EXAMINER

EWOLDT, GERALD R

ART UNIT	PAPER NUMBER
1644	

DATE MAILED: 02/14/2002

17

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 09/421,506	Applicant(s) Albani	
	Examiner G. R. Ewoldt	Art Unit 1644	
<i>-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --</i>			
Period for Reply			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>1</u> MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.			
<ul style="list-style-type: none"> - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). 			
Status			
1) <input checked="" type="checkbox"/> Responsive to communication(s) filed on <u>8/08/01 and 10/30/01</u>			
2a) <input type="checkbox"/> This action is FINAL . 2b) <input checked="" type="checkbox"/> This action is non-final.			
3) <input type="checkbox"/> Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.			
Disposition of Claims			
4) <input checked="" type="checkbox"/> Claim(s) <u>162-380</u> is/are pending in the application.			
5) <input type="checkbox"/> Claim(s) _____ is/are withdrawn from consideration.			
6) <input type="checkbox"/> Claim(s) _____ is/are allowed.			
7) <input type="checkbox"/> Claim(s) _____ is/are rejected.			
8) <input checked="" type="checkbox"/> Claims <u>162-380</u> are subject to restriction and/or election requirement.			
Application Papers			
9) <input type="checkbox"/> The specification is objected to by the Examiner.			
10) <input type="checkbox"/> The drawing(s) filed on _____ is/are objected to by the Examiner.			
11) <input type="checkbox"/> The proposed drawing correction filed on _____ is: a) <input type="checkbox"/> approved b) <input type="checkbox"/> disapproved.			
12) <input type="checkbox"/> The oath or declaration is objected to by the Examiner.			
Priority under 35 U.S.C. § 119			
13) <input type="checkbox"/> Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).			
a) <input type="checkbox"/> All b) <input type="checkbox"/> Some* c) <input type="checkbox"/> None of:			
1. <input type="checkbox"/> Certified copies of the priority documents have been received.			
2. <input type="checkbox"/> Certified copies of the priority documents have been received in Application No. _____.			
3. <input type="checkbox"/> Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).			
*See the attached detailed Office action for a list of the certified copies not received.			
14) <input type="checkbox"/> Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).			
Attachment(s)			
15) <input type="checkbox"/> Notice of References Cited (PTO-892)		18) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____	
16) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)		19) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)	
17) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____		20) <input type="checkbox"/> Other: _____	

DETAILED ACTION

1. The location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Dr. Gerald Ewoldt, Art Unit 1644, Technology Center 1600.

2. Applicant's election of Group I, Claims 1-26 in Paper No. 16, filed 10/30/01, is acknowledged. Upon reconsideration, however, the previous restriction requirement and election are vacated. A new restriction follows. The Examiner apologizes for any inconvenience or delay.

3. Restriction to one of the following inventions is required under 35 U.S.C. § 121:

1. Claim 162, drawn to a method of identifying T cells, classified in Class 435, subclass 7.1.
2. Claims 163-164 and 166-167, drawn to a method of isolating T cells, classified in Class 424, subclasses 278.1 and 534 and Class 435, subclass 7.1.
3. Claims 162-167, drawn to a method of characterizing T cells, classified in Class 424, subclasses 278.1 and 534 and Class 435, subclass 7.1.
4. Claims 168-170, 173-175, 186-188, drawn to a method of modulating a T cell response from Th1 to Th2, classified in Class 424, subclasses 278.1 and 534.
5. Claims 168, 171-175, 189-194, drawn to a method of modulating a T cell response from Th2 to Th1, classified in Class 424, subclasses 278.1 and 534.
6. Claims 176-185, drawn to a method of characterizing T cells comprising isolating mRNA, classified in Class 435, subclass 6.
7. Claim 195, drawn to a method of identifying T cells specific for graft epitopes, classified in Class 435, subclass 7.1.
8. Claim 196, drawn to a method of treating a recipient, classified in Class 424, subclass 184.1.

9. Claims 197-214, drawn to a kit, classified in Class 435, subclass 810.

10. Claim 215, drawn to an immunomodulatory column, classified in Class 435, subclass 283.1.

11. Claims 216-217, drawn to a method of identifying a gene, classified in Class 435, subclass 6.

12. Claim 218, drawn to a method of obtaining a population of T cells, classified in Class 435, subclasses 7.1 and 325.

13. Claim 219, drawn to a method of monitoring an immunological outcome, classified in Class 435, subclass 7.1.

14. Claims 220-221, drawn to an artificial antigen presenting cell (aAPC) comprising a liposome, an MHC component, an antigen, an accessory molecule, and an orienting molecule, classified in Class 435, subclass 325.

15. Claims 220-228, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, and a surfactant, classified in Class 435, subclass 325.

16. Claims 229-231 and 246-247, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, and a co-stimulatory molecule, classified in Class 435, subclass 325.

17. Claims 229-231, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, and an adhesion molecule, classified in Class 435, subclass 325.

18. Claims 229-231 and 273-274, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, and a cell modulation molecule, classified in Class 435, subclass 325.

19. Claims 229-231, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, and an irrelevant molecule, classified in Class 435, subclass 325.

20. Claims 232-240 and 248-255, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a co-stimulatory molecule, and a surfactant, classified in Class 435, subclass 325.

21. Claims 232-239 and 242, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, an adhesion molecule, and a surfactant, classified in Class 435, subclass 325.

22. Claims 232-239, 241, and 273-282, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a cell modulation molecule, and a surfactant, classified in Class 435, subclass 325.

23. Claims 232-239 and 243-245, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, an irrelevant molecule, and a surfactant, classified in Class 435, subclass 325.

24. Claims 246-247 and 256-258, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a co-stimulatory molecule, and an adhesion molecule, classified in Class 435, subclass 325.

25. Claims 246-247, 256-258, and 300-301, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a co-stimulatory molecule, and a cell modulation molecule, classified in Class 435, subclass 325.

26. Claims 246-247 and 256-258, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a co-stimulatory molecule, and an irrelevant molecule, classified in Class 435, subclass 325.

27. Claims 246-247 and 256-259, 262-267, and 269, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a co-stimulatory molecule, an adhesion molecule, and a surfactant, classified in Class 435, subclass 325.

28. Claims 246-247, 256-258, and 300-310, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a co-stimulatory molecule, a cell modulation molecule, and a surfactant, classified in Class 435, subclass 325.

29. Claims 246-247, 256-258, 262-267, and 270-272, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a co-stimulatory molecule, an irrelevant molecule, and a surfactant, classified in Class 435, subclass 325.

30. Claims 273-274 and 283-285, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a cell modulation molecule, and an adhesion molecule, classified in Class 435, subclass 325.

31. Claims 273-274 and 283-285, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a cell modulation molecule, and a cell modulation molecule, classified in Class 435, subclass 325.

32. Claims 273-274 and 283-285, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a cell modulation molecule, and an irrelevant molecule, classified in Class 435, subclass 325.

33. Claims 273-293, and 295-296, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a cell modulation molecule, an adhesion molecule, and a surfactant, classified in Class 435, subclass 325.

34. Claims 273-295, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a cell modulation molecule, a co-stimulatory molecule, and a surfactant, classified in Class 435, subclass 325.

35. Claims 273-293, 295, and 297-299, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a cell modulation molecule, an irrelevant molecule, and a surfactant, classified in Class 435, subclass 325.

36. Claims 300-301 and 311-313, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a co-stimulatory molecule, a cell modulation molecule, and an adhesion molecule, classified in Class 435, subclass 325.

37. Claims 300-301 and 311-313, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a co-stimulatory molecule, a cell modulation molecule, and an irrelevant molecule, classified in Class 435, subclass 325.

38. Claims 300-324, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a co-stimulatory molecule, a cell modulation molecule, an adhesion molecule, and a surfactant, classified in Class 435, subclass 325.

39. Claims 300-323 and 325-327, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a co-stimulatory molecule, a cell modulation molecule, an irrelevant molecule, and a surfactant, classified in Class 435, subclass 325.

40. Claims 328-341, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a co-stimulatory molecule, a cell modulation molecule, an adhesion molecule, an irrelevant molecule, and a surfactant, classified in Class 435, subclass 325.

41. Claims 342-343, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, and a solid support, classified in Class 435, subclass 325.

42. Claims 342-350, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a solid support, and a surfactant, classified in Class 435, subclass 325.

43. Claims 342-343 and 351-353, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a solid support, and a co-stimulatory molecule classified in Class 435, subclass 325.

44. Claims 342-343 and 351-353, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a solid support, and an adhesion molecule classified in Class 435, subclass 325.

45. Claims 342-343 and 351-353, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a solid support, and a cell modulation molecule classified in Class 435, subclass 325.

46. Claims 342-343 and 351-353, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a solid support, an irrelevant molecule, and a surfactant, classified in Class 435, subclass 325.

47. Claims 342-362, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a solid support, a co-stimulatory molecule, and a surfactant, classified in Class 435, subclass 325.

48. Claims 342-361 and 364, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a solid support, an adhesion molecule, and a surfactant, classified in Class 435, subclass 325.

49. Claims 342-361 and 363, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a solid support, a cell modulation molecule, and a surfactant, classified in Class 435, subclass 325.

50. Claims 342-361 and 366-367, drawn to an aAPC comprising a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a solid support, and an irrelevant molecule, and a surfactant, classified in Class 435, subclass 325.

51. Claims 369-380, drawn to a method of making an aAPC, classified in Class 435, subclass 325.

4. Inventions 9-10, and 14-50 are different products. The Inventions comprise different combinations of the components: a liposome, an MHC component, an antigen, an accessory molecule, an orienting molecule, a solid support, a co-stimulatory molecule, a cell modulation molecule, an adhesion molecule, an irrelevant molecule, and a surfactant. As the different components of the aAPC confer different properties on the artificial cell, each particular combination will comprise a product with distinct properties. Therefore the Inventions are patentably distinct.

5. Inventions 51 and 14-50 are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)).

In the instant case the product as claimed can be made by adding the antigen after the incorporation of the MHC complex.

6. Inventions 9-10, and 14-50, and 1-8 and 11-13 are related as products and processes of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. § 806.05(h)).

In the instant case, the products as claimed can be used in materially different processes, such as to produce antibodies.

7. Inventions 1-8, 11-13, and 51 are different methods. The methods employ different steps resulting in different end products or information. Therefore the methods are patentably distinct

8. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

9. Regardless of whichever Group Applicant should elect, Applicant is further required under 35 U.S.C. § 121 to elect:

- A) a **specific** lipid,
- B) a **specific** antigen,
- C) a **specific** MHC component,
- D) a **specific** accessory molecule,
- E) a **specific** orienting molecule,
- F) a **specific** co-stimulatory molecule, if one is desired,
- G) a **specific** adhesion molecule, if one is desired,
- H) a **specific** cell modulation molecule, if one is desired,
- I) a **specific** irrelevant molecule, if one is desired,
- I) a **specific** surfactant, if one is desired,

and list all Claims readable thereon including those subsequently added. Currently Claims 162-169, 171, 173-174, 176-185, 188, and 191-378 are generic.

10. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

The different lipids, antigens, MHC components, accessory molecules, orienting molecules, co-stimulatory molecules, adhesion molecules, cell modulation molecules, and irrelevant molecules, comprise different physiological properties, e.g., MHC class I's bind (and activate) different T cells than do MHC Class II's, and ICAMs bind different cells than do selectins. Therefore, the species are independent and patentable over one another.

11. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.

12. Any inquiry concerning this communication from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (703) 308-9805. The examiner can normally be reached Monday through Thursday from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973.

G.R. Ewoldt, Ph.D.
Patent Examiner
Technology Center 1600
February 07, 2002

Patrick J. Nolan
Patrick J. Nolan, Ph.D.
Primary Examiner
Technology Center 1600